Gene:
CYP2C19
cytochrome P450, family 2, subfamily C, polypeptide 19

Available Guidelines

  1. CPIC Guideline for amitriptyline and CYP2C19,CYP2D6
  2. CPIC Guideline for clomipramine and CYP2C19,CYP2D6
  3. CPIC Guideline for clopidogrel and CYP2C19
  4. CPIC Guideline for doxepin and CYP2C19,CYP2D6
  5. CPIC Guideline for imipramine and CYP2C19,CYP2D6
  6. CPIC Guideline for sertraline and CYP2C19
  7. CPIC Guideline for trimipramine and CYP2C19,CYP2D6
  8. CPIC Guideline for citalopram,escitalopram and CYP2C19
  9. DPWG Guideline for citalopram and CYP2C19
  10. DPWG Guideline for clopidogrel and CYP2C19
  11. DPWG Guideline for escitalopram and CYP2C19
  12. DPWG Guideline for esomeprazole and CYP2C19
  13. DPWG Guideline for imipramine and CYP2C19
  14. DPWG Guideline for lansoprazole and CYP2C19
  15. DPWG Guideline for moclobemide and CYP2C19
  16. DPWG Guideline for omeprazole and CYP2C19
  17. DPWG Guideline for pantoprazole and CYP2C19
  18. DPWG Guideline for rabeprazole and CYP2C19
  19. DPWG Guideline for sertraline and CYP2C19
  20. DPWG Guideline for voriconazole and CYP2C19

last updated 01/28/2016

1. CPIC Guideline for amitriptyline and CYP2C19,CYP2D6

Summary

The CPIC Dosing Guideline for amitriptyline recommends an alternative drug for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers.

There's more of this guideline. Read more.


last updated 01/16/2013

2. CPIC Guideline for clomipramine and CYP2C19,CYP2D6

Summary

Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including clomipramine. In the guideline for amitriptyline, an alternative drug is recommended for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers.

There's more of this guideline. Read more.


last updated 01/27/2016

3. CPIC Guideline for clopidogrel and CYP2C19

Summary

The CPIC Dosing Guideline for clopidogrel recommends an alternative antiplatelet therapy (e.g., prasugrel, ticagrelor) for CYP2C19 poor or intermediate metabolizers if there is no contraindicaiton.

There's more of this guideline. Read more.


last updated 07/13/2015

4. CPIC Guideline for doxepin and CYP2C19,CYP2D6

Summary

Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including doxepin. In the guideline for amitriptyline, an alternative drug is recommended for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers.

There's more of this guideline. Read more.


last updated 07/13/2015

5. CPIC Guideline for imipramine and CYP2C19,CYP2D6

Summary

Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including imipramine. In the guideline for amitriptyline, an alternative drug is recommended for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers.

There's more of this guideline. Read more.


last updated 01/27/2016

6. CPIC Guideline for sertraline and CYP2C19

Summary

The CPIC Dosing Guideline for the selective serotonin reuptake inhibitor sertraline recommends to consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 poor metabolizers.

There's more of this guideline. Read more.


last updated 07/13/2015

7. CPIC Guideline for trimipramine and CYP2C19,CYP2D6

Summary

Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6 to other tricyclics including trimipramine. In the guideline for amitriptyline, an alternative drug is recommended for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers.

There's more of this guideline. Read more.


last updated 01/27/2016

8. CPIC Guideline for citalopram,escitalopram and CYP2C19

Summary

The CPIC Dosing Guideline for the selective serotonin reuptake inhibitors citalopram and escitalopram recommends an alternative drug not predominantly metabolized by CYP2C19 for CYP2C19 ultrarapid metabolizers. For CYP2C19 poor metabolizers, consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.

There's more of this guideline. Read more.


last updated 08/10/2011

9. DPWG Guideline for citalopram and CYP2C19

Summary

For CYP2C19 ultrarapid metabolizers, monitor citalopram plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event, or select an alternative drug.

There's more of this guideline. Read more.


last updated 08/10/2011

10. DPWG Guideline for clopidogrel and CYP2C19

Summary

The Dutch Pharmacogenetics Working Group Guideline for clopidogrel recommends to consider an alternative drug for CYP2C19 poor or intermediate metabolizers, because of increased risk for reduced response to clopidogrel. Prasugrel might be associated with an increased bleeding risk compared to clopidogrel.

There's more of this guideline. Read more.


last updated 08/10/2011

11. DPWG Guideline for escitalopram and CYP2C19

Summary

For CYP2C19 ultrarapid metabolizers, monitor escitalopram plasma concentration and titrate dose to a maximum of 150% in response to efficacy and adverse drug event, or select alternative drug.

There's more of this guideline. Read more.



last updated 08/10/2011

13. DPWG Guideline for imipramine and CYP2C19

Summary

The Dutch Pharmacogenetics Working Group Guideline for imipramine recommends to reduce the dose by 30% in CYP2C19 poor metabolizers, and monitor the plasma concentration of imipramine and desipramine or select alternative drug. For CYP2C19 intermediate metabolizers, select an alternative drug.

There's more of this guideline. Read more.







last updated 08/10/2011

19. DPWG Guideline for sertraline and CYP2C19

Summary

Reduce sertraline dose by 50% for patients with CYP2C19 poor metabolizer genotypes (PM), and be extra alert to adverse drug events in patients with CYP2C19 intermediate metabolizer genotypes (IM).

There's more of this guideline. Read more.



PharmGKB annotates drug labels containing pharmacogenetic information approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency, Japan (PMDA), and Health Canada (Santé Canada) (HCSC). PharmGKB annotations provide a brief summary of the PGx in the label, an excerpt from the label and a downloadable highlighted label PDF file. A list of genes and phenotypes found within the label is mapped to label section headers and listed at the end of each annotation. PharmGKB also attempts to interpret the level of action implied in each label with the "PGx Level" tag.

See the legend for more information about drug label sources and PGx Levels.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA, PMDA, HCSC or other Medicine Agencies around the world - please contact feedback.


Annotated Labels

  1. FDA Label for carisoprodol and CYP2C19
  2. FDA Label for citalopram and CYP2C19,CYP2D6
  3. FDA Label for clobazam and CYP2C19
  4. FDA Label for clopidogrel and CYP2C19
  5. FDA Label for dexlansoprazole and CYP2C19
  6. FDA Label for diazepam and CYP2C19
  7. FDA Label for doxepin and CYP2C19,CYP2D6
  8. FDA Label for esomeprazole and CYP2C19
  9. FDA Label for lansoprazole and CYP2C19
  10. FDA Label for nelfinavir and CYP2C19,CYP3A
  11. FDA Label for omeprazole and CYP2C19
  12. FDA Label for pantoprazole and CYP2C19
  13. FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5
  14. FDA Label for rabeprazole and CYP2C19
  15. FDA Label for voriconazole and CYP2C19
  16. FDA Label for drospirenone,ethinyl estradiol and CYP2C19
  17. EMA Label for atazanavir and CYP2C19
  18. EMA Label for axitinib and CYP2C19,UGT1A1
  19. EMA Label for clopidogrel and CYP2C19
  20. EMA Label for esomeprazole and CYP2C19
  21. EMA Label for prasugrel and CYP2C19
  22. EMA Label for ticagrelor and CYP2C19
  23. EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4
  24. PMDA Label for clopidogrel and CYP2C19
  25. HCSC Label for citalopram and CYP2C19
  26. HCSC Label for clopidogrel and CYP2C19
  27. HCSC Label for dexlansoprazole and CYP2C19
  28. HCSC Label for esomeprazole and CYP2C19
  29. HCSC Label for omeprazole and CYP2C19
  30. HCSC Label for rabeprazole and CYP2C19
  31. HCSC Label for voriconazole and CYP2C19

last updated 10/25/2013

1. FDA Label for carisoprodol and CYP2C19

Actionable PGx

Summary

Carisoprodol (SOMA) should be used with caution in patients with reduced CYP2C19 activity. Published studies indicate that patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to carisoprodol and a 50% decreased exposure to meprobamate (a metabolite of carisoprodol) compared to normal CYP2C19 metabolizers.

There's more of this label. Read more.


last updated 10/25/2013

2. FDA Label for citalopram and CYP2C19,CYP2D6

Actionable PGx

Summary

The FDA-approved drug label recommends a maximum dose of 20 mg/day of citalopram (Celexa) in patients who are CYP2C19 poor metabolizers, due to an increase in citalopram exposure. This increased exposure leads to a greater risk for QT prolongation, a potentially fatal abnormality in the heart's electrical activity.

There's more of this label. Read more.


last updated 10/25/2013

3. FDA Label for clobazam and CYP2C19

Actionable PGx

Summary

In patients known to be CYP2C19 poor metabolizers, the drug label states that the initial dose of clobazam (ONFI) should be 5 mg/day. Patients can be titrated initially to 10 - 20 mg/day, and then titrated further to a maximum daily dose of 40 mg, if tolerated. This is due to an increase in levels of N-desmethylclobazam, the active metabolite of clobazam.

There's more of this label. Read more.


last updated 10/25/2013

4. FDA Label for clopidogrel and CYP2C19

Genetic testing recommended

Summary

The FDA-approved drug label for clopidogrel (Plavix) warns that patients who are CYP2C19 poor metabolizers may have diminished effectiveness of the drug, leading to higher cardiovascular event rates following acute coronary syndrome or percutaneous coronary intervention, as compared to patients with normal CYP2C19 function. The drug label suggests that alternative treatment or treatment strategies are considered in patients identified as CYP2C19 poor metabolizers.

There's more of this label. Read more.


last updated 10/25/2013

5. FDA Label for dexlansoprazole and CYP2C19

Actionable PGx

Summary

The FDA-approved drug label for dexlansoprazole (DEXILANT) notes that systemic exposure of the drug is generally higher in CYP2C19 intermediate and poor metabolizers, as compared to extensive metabolizers.

There's more of this label. Read more.


last updated 10/25/2013

6. FDA Label for diazepam and CYP2C19

Actionable PGx

Summary

The FDA-approved drug label for diazepam (Diastat) notes that the drug is metabolized by CYP2C19 and CYP3A4, and that inter-individual variation in clearance of the drug is likely attributable to CYP2C19 or CYP3A4 genetic variability.

There's more of this label. Read more.


last updated 06/01/2015

7. FDA Label for doxepin and CYP2C19,CYP2D6

Actionable PGx

Summary

Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6. The drug label notes that CYP2D6 and CYP2C19 poor metabolizers have higher than expected plasma concentrations of doxepin when given typical doses. Additionally, inhibitors of these CYP isozymes may increase the exposure of doxepin.

There's more of this label. Read more.


last updated 10/25/2013

8. FDA Label for esomeprazole and CYP2C19

Actionable PGx

Summary

The FDA-approved drug label for esomeprazole (NEXIUM) notes that individuals who are CYP2C19 poor metabolizers may have double the steady state area under the plasma concentration-time curve (AUC) of esomeprazole compared to extensive metabolizers.

There's more of this label. Read more.


last updated 10/25/2013

9. FDA Label for lansoprazole and CYP2C19

Informative PGx

Summary

Lansoprazole delayed-release capsules are metabolized mainly by CYP3A and CYP2C19 isozymes. Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19

There's more of this label. Read more.


last updated 10/25/2013

10. FDA Label for nelfinavir and CYP2C19,CYP3A

Informative PGx

Summary

Coadministration of VIRACEPT with drugs primarily metabolized by CYP3A may result in increased plasma concentrations of the other drug that could prolong its therapeutic and adverse effects. Coadministration of VIRACEPT and drugs that induce CYP3A or CYP2C19 may decrease nelfinavir plasma concentrations and reduce its therapeutic effect. Coadministration of VIRACEPT and drugs that inhibit CYP3A or CYP2C19 may increase nelfinavir plasma concentrations.

There's more of this label. Read more.



last updated 10/25/2013

12. FDA Label for pantoprazole and CYP2C19

Actionable PGx

Summary

Pantoprazole is metabolized mainly by CYP2C19 and to minor extents by CYPs 3A4, 2D6, and 2C9. For adult patients who are CYP2C19 poor metabolizers, no dosage adjustment is needed. For known pediatric poor metabolizers, a dose reduction should be considered.

There's more of this label. Read more.



last updated 12/12/2015

14. FDA Label for rabeprazole and CYP2C19

Informative PGx

Summary

Rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) and cytochrome P450 2C19 (CYP2C19). Patients with the CYP2C19 poor metabolizer genotypes may have slower rabeprazole metabolism and increased suppression of gastric acid as compared to more extensive metabolizers.

There's more of this label. Read more.


last updated 08/28/2015

15. FDA Label for voriconazole and CYP2C19

Actionable PGx

Summary

Voriconazole is an antifungal used to treat serious infections of Aspergillus fumigatu, Candida, Scedosporium, Fusarium and other species. Voriconazole is metabolized in the liver by CYP2C19, CYP2C9 and CYP3A4. It also influences expression of metabolizing enzymes and interacts with several other drugs.

There's more of this label. Read more.


last updated 07/14/2014

16. FDA Label for drospirenone,ethinyl estradiol and CYP2C19

Informative PGx

Summary

The FDA-approved drug label for drospirenone and ethinyl estradiol (Yaz) notes that in vitro studies showed an inhibitory effect of drospirenone on the turnover of model substrates of CYP1A1, CYP2C9, CYP2C19 and CYP3A4. However, in vivo studies using omeprazole as a marker substrate showed that drospirenone has little propensity to interact to a significant extent with cytochrome P450 enzymes at a clinical dose level.

There's more of this label. Read more.


last updated 09/16/2014

17. EMA Label for atazanavir and CYP2C19

Genetic testing recommended

Summary

The EMA European Public Assessment Report (EPAR) for atazanavir (Reyataz) contains pharmacogenetic information related to co-treatment with voriconazole and ritonavir: both atazanavir and voriconazole exposure is expected to be increased in patients who do not have a functional CYP2C19 allele. The EPAR states that at the time of voriconazole treatment, a test for CYP2C19 genotype should be performed if feasible, and provides therapeutic recommendations based on CYP2C19 genotype.

There's more of this label. Read more.


last updated 09/12/2014

18. EMA Label for axitinib and CYP2C19,UGT1A1

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for axitinib contains pharmacogenetic information related to there being no clinically relevant effects of UGT1A1 genotype or CYP2C19 genotype on axitinib pharmacokinetics.

There's more of this label. Read more.


last updated 10/29/2015

19. EMA Label for clopidogrel and CYP2C19

Actionable PGx

Summary

The EMA European Public Assessment Report (EPAR) contains information regarding a diminished response to clopidogrel in CYP2C19 poor metabolizers. It also precautions the use of concomitant drugs that are CYP2C19 inhibitors.

There's more of this label. Read more.


last updated 10/29/2015

20. EMA Label for esomeprazole and CYP2C19

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for esomeprazole (Nexium Control) notes that CYP2C19 poor metabolizers have higher plasma concentrations of the drug compared to extensive metabolizers, but there are no implications for dosing.

There's more of this label. Read more.


last updated 10/29/2015

21. EMA Label for prasugrel and CYP2C19

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for prasugrel (Efient) contains information regarding the lack of effect of genetic variants in the CYP3A5, CYP2B6, CYP2C9 and CYP2C19 genes on the pharmacokinetics of prasugrel or response.

There's more of this label. Read more.


last updated 10/29/2015

22. EMA Label for ticagrelor and CYP2C19

Actionable PGx

Summary

The EMA European Public Assessment Report (EPAR) for ticagrelor (Brilique) contains information regarding a study in which CYP2C19 and ABCB1 genotyping was carried out (PLATO - platelet inhibition and patient outcomes). In patients with one or more CYP2C19 loss of function allele, non-coronary artery by-pass grafting (non-CABG) PLATO major bleeding was increased when treated with ticagrelor compared to clopidogrel, but was similar in patients with no loss of function alleles.

There's more of this label. Read more.


last updated 10/29/2015

23. EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.

There's more of this label. Read more.


last updated 01/26/2015

24. PMDA Label for clopidogrel and CYP2C19

Actionable PGx

Summary

The PMDA package insert for clopidogrel states that in clinical trials, individuals who were CYP2C19 intermediate or poor metabolizers had a higher rate of cardiovascular events as compared to those who were CYP2C19 extensive metabolizers.

There's more of this label. Read more.


last updated 06/08/2015

25. HCSC Label for citalopram and CYP2C19

Actionable PGx

Summary

The product monograph for citalopram recommends that patients who are CYP2C19 poor metabolizers receive an initial dose of 10 mg daily during the first two weeks of treatment, and should not receive a dose of greater than 20 mg/day. However, it makes no statements regarding genetic testing of CYP2C19 prior to treatment.

There's more of this label. Read more.


last updated 06/08/2015

26. HCSC Label for clopidogrel and CYP2C19

Actionable PGx

Summary

The product monograph for clopidogrel (PLAVIX) states that CYP2C19 poor metabolizers may be at increased risk for experiencing cardiovascular events when taking the drug at recommended doses as compared to normal CYP2C19 metabolizers, and that an alternative treatment or treatment strategies should be considered in these patients.

There's more of this label. Read more.


last updated 06/08/2015

27. HCSC Label for dexlansoprazole and CYP2C19

Actionable PGx

Summary

The product monograph for dexlansoprazole (DEXILANT) notes that CYP2C19 intermediate and poor metabolizers generally have higher exposure to the drug as compared to extensive metabolizers.

There's more of this label. Read more.


last updated 06/08/2015

28. HCSC Label for esomeprazole and CYP2C19

Informative PGx

Summary

The product monograph for esomeprazole states that CYP2C19 poor metabolizers have increased concentrations of the drug as compared to the rest of the population, but that dosage adjustment based on CYP2C19 genotype is not necessary.

There's more of this label. Read more.


last updated 06/08/2015

29. HCSC Label for omeprazole and CYP2C19

Informative PGx

Summary

The product monograph for omeprazole (LOSEC) states that CYP2C19 poor metabolizers have higher plasma concentrations of the drug as compared to extensive metabolizers. However, the monograph also notes that this has no implication on dosing of omeprazole.

There's more of this label. Read more.


last updated 06/08/2015

30. HCSC Label for rabeprazole and CYP2C19

Actionable PGx

Summary

The product monograph for rabeprazole states that individuals with CYP2C19 deficiency have reduced metabolism of rabeprazole.

There's more of this label. Read more.


last updated 08/28/2015

31. HCSC Label for voriconazole and CYP2C19

Actionable PGx

Summary

The product monograph for voriconazole notes that CYP2C19 poor metabolizers have, on average, 4-fold higher exposure to the drug as compared to extensive metabolizers. However, the product monograph does not make any statements regarding genetic testing of CYP2C19 prior to treatment.

There's more of this label. Read more.


Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below. Please follow the link in the "Position" column for more information about a particular variant. Each link in the "Position" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for CYP2C19

Variant?
(146)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA *1 N/A N/A N/A
No VIP available No VIP available VA *1A N/A N/A N/A
No VIP available No VIP available VA *1B N/A N/A N/A
No VIP available No VIP available VA *1C N/A N/A N/A
No VIP available CA VA *2 N/A N/A N/A
No VIP available No VIP available VA *2A N/A N/A N/A
No VIP available No VIP available VA *2B N/A N/A N/A
No VIP available No VIP available VA *2C N/A N/A N/A
No VIP available No VIP available VA *2D N/A N/A N/A
No VIP available CA VA *3 N/A N/A N/A
No VIP available No VIP available VA *3A N/A N/A N/A
No VIP available No VIP available VA *3B N/A N/A N/A
No VIP available CA VA *4 N/A N/A N/A
No VIP available CA VA *5 N/A N/A N/A
No VIP available No VIP available VA *5A N/A N/A N/A
No VIP available No VIP available VA *5B N/A N/A N/A
No VIP available CA VA *6 N/A N/A N/A
No VIP available CA VA *7 N/A N/A N/A
No VIP available CA VA *8 N/A N/A N/A
No VIP available CA VA *9 N/A N/A N/A
No VIP available CA VA *10 N/A N/A N/A
No VIP available CA VA *11 N/A N/A N/A
No VIP available No VIP available VA *12 N/A N/A N/A
No VIP available CA VA *13 N/A N/A N/A
No VIP available CA VA *14 N/A N/A N/A
No VIP available CA VA *15 N/A N/A N/A
No VIP available CA VA *16 N/A N/A N/A
No VIP available CA VA *17 N/A N/A N/A
No VIP available CA VA *18 N/A N/A N/A
No VIP available CA VA *19 N/A N/A N/A
No VIP available CA VA *22 N/A N/A N/A
No VIP available CA VA *23 N/A N/A N/A
No VIP available CA VA *24 N/A N/A N/A
No VIP available CA VA *25 N/A N/A N/A
No VIP available CA VA *26 N/A N/A N/A
No VIP available No VIP available VA *27 N/A N/A N/A
No VIP available CA VA *28 N/A N/A N/A
No VIP available No Clinical Annotations available CYP2C19 poor metabolizer genotype
CYP2C19 poor metabolizer genotype N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C19 ultrarapid metabolizer phenotype N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C19 extensive metabolizers N/A N/A N/A
No VIP available No Clinical Annotations available CYP2C19 intermediate metabolizers
CYP2C19 intermediate metabolizers N/A N/A N/A
No VIP available No Clinical Annotations available CYP2C19 ultrarapid metabolizer
CYP2C19 ultrarapid metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available CYP2C19 intermediate metabolizer
CYP2C19 intermediate metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available CYP2C19 poor metabolizer
CYP2C19 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available CYP2C19 poor metabolizers and intermediate metabolizers
CYP2C19 poor metabolizers and intermediate metabolizers N/A N/A N/A
No VIP available No Clinical Annotations available CYP2C19 poor metabolizer and intermediate metabolizer genotypes
CYP2C19 poor metabolizer and intermediate metabolizer genotypes N/A N/A N/A
No VIP available No Clinical Annotations available CYP2C19 poor metabolizers
CYP2C19 poor metabolizers N/A N/A N/A
No VIP available CA VA
rs11188072 -3402, 1599C>T, 47323525C>T, 96519061C>T, CYP2C19:, CYP2C19: -3402C>T, part of CYP2C19*17
C > T
Not Available
rs12248560 -806C>A, -806C>T, 4195C>A, 4195C>T, 47326121C>A, 47326121C>T, 96521657C>A, 96521657C>T, CYP2C19*17, CYP2C19*17 CYP2C19: -806C>T, CYP2C19: -806C>T
C > T
C > A
5' Flanking
No VIP available CA VA
rs12768009 168+3235G>A, 47330329G>A, 8403G>A, 8621C>T, 96525865G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs12769205 17662A>G, 332-23A>G, 94775367A>G, 96535124A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs145119820
G > A
Missense
Val113Ile
No VIP available CA VA
rs28399504 1A>G, 47326927A>G, 5001A>G, 80161A>G, 96522463A>G, 99C>T, CYP2C19*4, CYP2C19:A1G, Met1Val
A > G
Missense
Met1Val
No VIP available No Clinical Annotations available VA
rs3814637 -1418C>G, -1418C>T, 3583C>G, 3583C>T, 47325509C>G, 47325509C>T, 96521045C>G, 96521045C>T
C > G
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs41291556 12711T>C, 17711T>C, 358T>C, 47339637T>C, 96535173T>C, CYP2C19:358T>C, T358C, Trp120Arg, W120R
T > C
Missense
Trp120Arg
rs4244285 24154G>A, 681G>A, 94781859G>A, 96541616G>A, CYP2C19*2, CYP2C19:681G>A, CYP2C19:G681A, Pro227=
G > A
G > C
Synonymous
Pro227Pro
rs4986893 22948G>A, 47344874G>A, 636G>A, 96540410G>A, CYP2C19*3, CYP2C19:636G>A, CYP2C19:G636A, Trp212Ter
G > A
Stop Codon
Trp212null
No VIP available No Clinical Annotations available VA
rs55948420 1180G>A, 47414168G>A, 92242G>A, 96609704G>A, Val394Met
G > A
Missense
Val394Met
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 146

Overview

Alternate Names:  CYP2C
Alternate Symbols:  CPCJ; P450IIC19
PharmGKB Accession Id: PA124

Details

Cytogenetic Location: chr10 : q23.33 - q23.33
GP mRNA Boundary: chr10 : 96522463 - 96612671
GP Gene Boundary: chr10 : 96512463 - 96615671
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Introduction
The cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) gene is located within a cluster of cytochrome P450 genes (Centromere-CYP2C18-CYP2C19-CYP2C9-CYP2C8-Telomere) on chromosome 10q23.33. The CYP2C19 enzyme contributes to the metabolism of a large number of clinically relevant drugs and drug classes such as antidepressants [Article:15199661], benzodiazepines [Article:8148870], mephenytoin [Article:8195181], proton pump inhibitors (PPIs) [Article:15258107], and the antiplatelet prodrug clopidogrel [Article:16772608]. Like other CYP450 genes, inherited genetic variation in CYP2C19 and its variable hepatic expression contributes to interindividual phenotypic variability in CYP2C19-substrate metabolism. The CYP2C19 "poor metabolism" phenotype was initially discovered by studies on impaired mephenytoin metabolism and the major molecular defect responsible for the trait is the CYP2C19*2 (c.681G>A; rs4244285) loss-of-function allele [Article:8195181]. CYP2C19 genotype has since been shown to affect the metabolism of several drugs and clinical CYP2C19 genetic testing is currently available [Article:21716271, 21412232].

Expression
CYP2C19 is predominantly expressed in the liver and, to a lesser extent, in the small intestine [Article:10487415]. Constitutive expression of CYP2C19 is largely mediated by hepatic nuclear factors 4 alpha (HNF4alpha, HNF4A) and 3 gamma (HNF3gamma, FOXA3) [Article:17827783, 17576804, 15130783], and transcriptional activation is mediated by the drug responsive nuclear receptors CAR (NR1I3), PXR (NR1I2), and GRalpha (NR3C1) [Article:12869636, 11181490], suggesting regulation by endogenous hormones and by drugs such as rifampicin [Article:2223426, 20086032]. In addition to rifampicin, human CYP2C19 can be induced by ritonavir, nelfinavir, hyperforin, St. John's wort, dexamethasone, and artemisinin [Article:19702536]. In vitro expression studies have recently shown that the GATA-4 (GATA4) transcription factor also upregulates CYP2C19 transcriptional activity by binding to two predicted GATA-specific promoter elements [Article:20206639]. Reduced CYP2C19 activity among women using steroid oral contraceptives results from transcriptional down-regulation of CYP2C19 expression through binding of ligand-activated estrogen receptor alpha to a specific ERE consensus half-site in the CYP2C19 promoter [Article:20675569].

Certain selective serotonin reuptake inhibitors (SSRIs; e.g., fluoxetine, fluvoxamine) [Article:18691982, 8880055] and PPIs (e.g. omeprazole, and lansoprazole) [Article:11309556, 9433390, 9224780] have an inhibitory effect on CYP2C19, which may cause drug-drug interactions with co-administered CYP2C19-metabolized drugs. For example, early studies suggested that omeprazole (a common PPI) diminished the pharmacodynamic antiplatelet effects of clopidogrel and increased corresponding cardiovascular risks [Article:19258584, 18206732]. However, it is currently not clear if identified changes in ex vivo platelet aggregation due to concomitant omeprazole and clopidogrel administration translates into clinically meaningful outcome differences (for review see [Article:21126648]).

Clinical CYP2C19 Pharmacogenetic Testing
Although a number of genotyping technologies can be used to interrogate variant CYP2C19 alleles in Clinical Laboratory Improvement Amendments (CLIA)-approved laboratories, two genotyping platforms have been approved by the U.S. Food and Drug Administration (FDA) at the time of this writing: the AmpliChip‚® CYP450 Test (Roche Molecular Systems, Inc., Pleasanton, CA) that interrogates CYP2C19*2 and *3 (plus CYP2D6 variant alleles) and the Infiniti‚® CYP2C19 Assay (AutoGenomics, Inc., Vista, CA) that interrogates CYP2C19*2, *3, and *17. For test interpretation and clopidogrel dosing suggestions, see the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 genotype and clopidogrel therapy [Article:21716271]. Additionally, a recent clinical pharmacogenetics practice review provides dosing guidelines for clopidogrel and other CYP2C19-metabolized drugs [Article:21412232] and CYP2C19/CYP2D6 genotype-based antidepressant dosing recommendations have been previously reported [Article:11531654].

Citation PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics and genomics. 2011. Scott Stuart A, Sangkuhl Katrin, Shuldiner Alan R, Hulot Jean-Sébastien, Thorn Caroline F, Altman Russ B, Klein Teri E. PubMed
History

Submitted by Jason Robarge, Rebecca Fletcher, Anne Nguyen (COBRA), Caroline F. Thorn

Updated by Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF

Variant Summaries rs12248560, rs4244285, rs4986893
Haplotype Summaries CYP2C19*3, CYP2C19*2, CYP2C19*17
Drugs
Phenotypes Poor Metabolizer

Haplotype Overview

Haplotypes in the "CYP2C19 Cytochrome P450 Nomenclature DB Haplotype Set" are derived from the Human Cytochrome P450 (CYP) Allele Nomenclature Database. The Human Cytochrome P450 (CYP) Allele Nomenclature Database states that nucleotide changes listed below are based on NCBI Reference Sequence NT_030059.13. Note that the nucleotide positions from the Human Cytochrome P450 (CYP) Allele Nomenclature Database do not directly match the given NCBI reference sequence. For questions about nucleotide positions, please contact the Human Cytochrome P450 (CYP) Allele Nomenclature Database directly, as they are the authoritative source on cytochrome P450 nomenclature.

PharmGKB has added some alleles below (e.g. the rows for *1 and *2), inserted for star alleles with subgroups (e.g. A, B etc). These rows reflect only the defining SNP for the star allele to accommodate how the star allele is referred to in the literature.

Haplotypes in the "CPIC CYP2C19 Haplotype Set" are derived from the supplemental tables in the CPIC guidelines involving CYP2C19.

Last updated 8/11/15.

The Translational Pharmacogenetics Project (TPP) is a PGRN-led initiative with the goal to operationalize the work of CPIC by translating widely accepted actionable pharmacogenetics discoveries into real-world clinical practice. Download the TPP file for CYP2C19 here: CYP2C19 lookup table and CYP2C19 work flow document (updated 2 July 2014).

Source: PharmGKB

CYP2C19 Cytochrome P450 Nomenclature DB Haplotype Set

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Carbamazepine Pathway, Pharmacokinetics
    Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.
  1. Citalopram Pathway, Pharmacokinetics
    Pharmacokinetics of the selective serotonin reuptake inhibitor citalopram.
  1. Clomipramine Pathway, Pharmacokinetics
    Schematic representation of clomipramine metabolism in human liver.
  1. Clopidogrel Pathway, Pharmacokinetics
    Clopidogrel metabolism.
  1. Cyclophosphamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of cyclophosphamide.
  1. Doxepin Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of the tricyclic doxepin.
  1. Fluoxetine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of fluoxetine.
  1. Fluvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Gefitinib Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the transportation and metabolism of gefitinib.
  1. Glucocorticoid Pathway - Transcription Regulation, Pharmacodynamics
    Model displaying genes which may be involved in the nuclear complex formed that regulates transcription in response to glucocorticoids.
  1. Ibuprofen Pathway, Pharmacokinetics
    Stylized diagram of metabolism and transport of ibuprofen in the liver and kidney.
  1. Imipramine/Desipramine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of the tricyclic antidepressants imipramine and desipramine.
  1. Paroxetine Pathway, Pharmacokinetics
    Genes involved in the metabolism of paroxetine and in the mechanism of action.
  1. Phenytoin Pathway, Pharmacokinetics
    Genes involved in the metabolism of phenytoin in the human liver cell.
  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.
  1. Proton Pump Inhibitor Pathway, Pharmacokinetics
    Omeprazole metabolism in the liver.
  1. Statin Pathway - Generalized, Pharmacokinetics
    Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.
  1. Tamoxifen Pathway, Pharmacokinetics
    Tamoxifen metabolism in the liver.
  1. Venlafaxine Pathway, Pharmacokinetics
    Stylized cells depicting the metabolism and mechanism of action of venlafaxine.
  1. Warfarin Pathway, Pharmacokinetics
    Representation of the candidate genes involved in transport, metabolism and clearance of warfarin.

External Pathways

Links to non-PharmGKB pathways.

  1. Xenobiotics - (Reactome via Pathway Interaction Database)

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C9

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
3-cyano-7-ethoxycoumarin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
4-hydroxytamoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abacavir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abiraterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
acamprosate
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
acenocoumarol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
acetaminophen
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
afatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alemtuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alfentanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
almotriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alosetron
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alprazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amantadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ambrisentan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aminophenazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amiodarone
amitriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amlodipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amodiaquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amoxicillin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amphetamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amphotericin b
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
anastrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
apomorphine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
arformoterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aripiprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
arsenic trioxide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
artemisinin
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
aspirin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
astemizole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atazanavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atenolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atomoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
atorvastatin
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
axitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
azacitidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
azathioprine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
benztropine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
biperiden
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
boceprevir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bromazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bromocriptine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
buprenorphine
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
bupropion
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
buspirone
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
busulfan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cabergoline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
caffeine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
capecitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
carbamazepine
carisoprodol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
carvedilol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
celecoxib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cerivastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cetuximab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cevimeline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
chloramphenicol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorcycloguanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chloroquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorpheniramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorzoxazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
cilostazol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
cimetidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cisapride
citalopram
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clarithromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clavulanate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clindamycin
No Dosing Guideline available DL CA VA No VIP available No VIP available
clobazam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clofibrate
clomipramine
clopidogrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clotrimazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
clozapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
codeine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
coumarin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
crizotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyclobenzaprine
cyclophosphamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyclosporine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dabrafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dapsone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
darunavir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dasatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
daunorubicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
debrisoquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
desipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexamethasone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexfenfluramine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexlansoprazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dextromethorphan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diatrizoate
diazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diclofenac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
didanosine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
digoxin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diphenhydramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dipyridamole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
disulfiram
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
docetaxel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
donepezil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dopamine
doxepin
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
doxorubicin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
drospirenone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
duloxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
efavirenz
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eletriptan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eltrombopag
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
elvitegravir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
emtricitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
endoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
enflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
entacapone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
erlotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
erythromycin
DG No Drug Label available CA VA No VIP available No VIP available
escitalopram
esomeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eszopiclone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ethambutol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ethanol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ethinyl estradiol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
etodolac
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
etravirine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
exemestane
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
famotidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
felbamate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
felodipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fenfluramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fenofibrate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fentanyl
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flecainide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flucloxacillin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flunarizine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
flunitrazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluorouracil
fluoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluphenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flurazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flurbiprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluticasone propionate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
fluvastatin
fluvoxamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
frovatriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fulvestrant
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
furafylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
furosemide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
gefitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemcitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemfibrozil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemtuzumab ozogamicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ginkgo biloba
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ginkgo biloba extract
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
glibenclamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
glipizide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
glucosamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
haloperidol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
halothane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
hexobarbital
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydralazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydrochlorothiazide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydrocodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydrocortisone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydromorphone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydroxyzine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ibuprofen
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
icotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
iloperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
imatinib
imipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
indacaterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
indinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
indomethacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
interferon alfa-2a, recombinant
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
irbesartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
irinotecan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isoflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
isoniazid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isotretinoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
itraconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor / lumacaftor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ketamine
ketoconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
labetalol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lafutidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lamivudine
lansoprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lapatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
leflunomide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lenalidomide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
letrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levodopa
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levothyroxine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lisinopril
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lisuride
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lomitapide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lopinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
loratadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
losartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
lovastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
loxapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
maprotiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
maraviroc
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
medroxyprogesterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
meloxicam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
meperidine
mephenytoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mercaptopurine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metformin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
methadone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methotrexate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methylcholanthrene
methylphenobarbital
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metoclopramide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
metoprolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metronidazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mianserin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
midazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
mirtazapine
moclobemide
modafinil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
montelukast
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
morphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mycophenolate mofetil
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
n-desmethyltamoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naltrexone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naproxen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naratriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naringenin
nelfinavir
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
nevirapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nicergoline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nicotine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nilotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nilutamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
norethindrone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
nortriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Noscapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
olanzapine
omeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oseltamivir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxaliplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
oxazepam
oxcarbazepine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxycodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
paclitaxel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
panitumumab
pantoprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
paroxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
peginterferon alfa-2a
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
peginterferon alfa-2b
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pentobarbital
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pergolide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
perphenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pertuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phencyclidine
phenobarbital
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenprocoumon
phenytoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pimozide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pioglitazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
piroxicam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pitavastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
posaconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pramipexole
No Dosing Guideline available DL CA VA No VIP available No VIP available
prasugrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pravastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
prednisone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
primaquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
primidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
probenecid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
procainamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prochlorperazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
progesterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
proguanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
promethazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propafenone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propofol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propoxyphene
propranolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
protriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
pyrazinamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
quetiapine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinidine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinine
rabeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
raltegravir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ramipril
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rasagiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rasburicase
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
regorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
reserpine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ribavirin
rifampin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
risperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ritonavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rofecoxib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ropinirole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rosiglitazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
rosuvastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
salmeterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
saquinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
selegiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sertindole
DG No Drug Label available CA VA No VIP available No VIP available
sertraline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sevoflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sibutramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sildenafil
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
simeprevir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
simvastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sirolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sparteine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
stavudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfamethoxazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfaphenazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfasalazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sunitinib
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
tacrolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tadalafil
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
tamoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tamsulosin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tegafur
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telaprevir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
temazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
temsirolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
teniposide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tenofovir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terazosin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terbinafine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terfenadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terodiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
testosterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tetrabenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tetracycline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
theophylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thioguanine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thioridazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thiotepa
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ticagrelor
ticlopidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
timolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tiotropium
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tipranavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tizanidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
tolbutamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolcapone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolterodine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
topiramate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
toremifene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tramadol
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
tranylcypromine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trastuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trazodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tretinoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
triamterene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
triazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trifluoperazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trihexyphenidyl
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trimethadione
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trimethoprim
DG No Drug Label available CA VA No VIP available No VIP available
trimipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
troglitazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
troleandomycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
valproic acid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
valsartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
varenicline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vemurafenib
venlafaxine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
verapamil
voriconazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vortioxetine
warfarin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zalcitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zidovudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ziprasidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zolmitriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zolpidem
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zuclopenthixol

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acquired Immunodeficiency Syndrome
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Acute coronary syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
adverse events
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alcoholism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alzheimer Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Angina Pectoris
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angina, Unstable
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anxiety Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmias, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Arthritis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis, Rheumatoid
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Asthma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atrial Fibrillation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Attention Deficit Disorder with Hyperactivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Autistic Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Non-Small-Cell Lung
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Renal Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carcinoma, Squamous Cell
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cardiovascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cerebrovascular Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colonic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colorectal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
composite endpoints (transient ischemic attack (tia), stroke, myocardial infarction, or death)
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Coronary Artery Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Coronary Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Crohn Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cystic Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Death
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Death, Sudden, Cardiac
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Depression
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Depressive Disorder
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Depressive Disorder, Major
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Diabetic Retinopathy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interaction with drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Resistance
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Elderly Adult
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
electrocardiogram qt prolonged
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epidermal Necrolysis, Toxic
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Esophagitis
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Esophagitis, Peptic
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
event-free survival
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gastroesophageal Reflux
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Stromal Tumors
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
gastrointestinal toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gilbert's syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gingival Hyperplasia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Graft vs Host Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Granulomatous Disease, Chronic
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Heart Failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
heart valve replacement
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Helicobacter Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hematologic Diseases
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
hemopoietic stem cell transplant
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hemorrhage
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hepatitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hepatitis C
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
HIV
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HIV Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperbilirubinemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypereosinophilic Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperlipidemias
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperlipoproteinemia Type II
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hyperprolactinemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypertension, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypoglycemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Infection
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammatory Bowel Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
intragastric ph
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ischemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Ischemic Attack, Transient
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Kidney Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leishmaniasis, Visceral
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Lymphocytic, Chronic, B-Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Nonlymphocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Promyelocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Leukopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long QT Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lung Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lung transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lupus erythematosus
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Lupus Erythematosus, Systemic
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lupus Nephritis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Maculopapular Exanthema
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
major adverse cardiac events (mace)
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Mental Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metabolic syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Migraine without Aura
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Muscular Diseases
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Myelodysplastic Syndromes
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Myocardial Infarction
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Myocardial Ischemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neoplasm Metastasis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nephrotoxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Neurologic Manifestations
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neurotoxicity Syndromes
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Obesity
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Obsessive-Compulsive Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ocular Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Opioid-Related Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ovarian Failure, Premature
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
over-anticoagulation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
overall survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pain
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pancreatic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Parkinson Disease
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Peptic Ulcer
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peripheral Vascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharyngitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
platelet aggregation inhibition
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
platelet reactivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pregnancy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Psoriasis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Disease, Chronic Obstructive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Recurrence
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Recurrence free survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Respiratory Tract Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rhabdomyolysis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
secondary composite endpoints (transient ischemic attack (tia), stroke, or death)
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Seizures
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
serum anticholinergic activity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Severe Combined Immunodeficiency
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Shock, Septic
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sjogren's Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stevens-Johnson Syndrome
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Substance-Related Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
suicide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thromboembolism
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Tobacco Use Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Torsades de Pointes
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Toxic liver disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
treatment failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Tuberculosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tuberculosis, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tumor Lysis Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Ulcer
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary Incontinence
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Vasculitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vision Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Wegener Granulomatosis

Publications related to CYP2C19: 694

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Navigating pleiotropy in precision medicine: pharmacogenes from trauma to behavioral health. Pharmacogenomics. 2016. Oberg Vicki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma. JAMA dermatology. 2016. Williams Kiyanna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. Journal of atherosclerosis and thrombosis. 2016. Yi Xingyang, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms. International journal of antimicrobial agents. 2016. Cendejas-Bueno Emilio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. Pharmacogenomics. 2016. Schirmer Jan Henrik, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of CYP2C19*2 and Associated Haplotypes with Lower Norendoxifen Levels in Tamoxifen-treated Asian Breast Cancer Patients. British journal of clinical pharmacology. 2016. Lim Joanne Siok Liu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Clinical and translational science. 2016. Khalil B M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis. Drug metabolism and pharmacokinetics. 2016. Sumonrat Chuwongwattana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. International journal of clinical pharmacy. 2016. Yuce-Artun Nazan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians. Genetics in medicine : official journal of the American College of Medical Genetics. 2015. Park Mahn-Won, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. International journal of antimicrobial agents. 2015. Lamoureux Fabien, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genotype - Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015. Teusink A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. Journal of neurosurgery. 2015. Hoh Brian L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction. Platelets. 2015. Lee Ji Hyun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese systemic lupus erythematosus patients. British journal of clinical pharmacology. 2015. Shu Wenying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. British journal of clinical pharmacology. 2015. Kim Ho-Sook, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. Clinical immunology (Orlando, Fla.). 2015. Wang Hong-Na, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic Allele Nomenclature: International Workgroup Recommendations for Test Result Reporting. Clinical pharmacology and therapeutics. 2015. Kalman Lisa V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. Journal of human genetics. 2015. Jittikoon Jiraphun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. Journal of clinical pharmacy and therapeutics. 2015. Uckun Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. Pharmacogenetics and genomics. 2015. Jiang Minghuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in the human cytochrome P450 supergene family. Pharmacogenetics and genomics. 2015. Fujikura Kohei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. The pharmacogenomics journal. 2015. Shirasaka Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thrombosis research. 2015. Calderón-Cruz Beatriz, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. European journal of clinical pharmacology. 2015. Collet Jean-Philippe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series. Intensive care medicine. 2015. Weigel Joachim D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of Cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. Journal of clinical pharmacology. 2015. Imamura Chiyo K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenetics and genomics. 2015. Bishop Jeffrey R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Pharmacogenomics. 2015. Brown Jacob T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype. British journal of clinical pharmacology. 2015. Bennis Youssef, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect. European journal of clinical pharmacology. 2015. Hu Pei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype. Basic & clinical pharmacology & toxicology. 2015. Markert Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients. British journal of clinical pharmacology. 2015. Lanchote Vera Lucia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical pharmacology and therapeutics. 2015. Hicks J Kevin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19*17 genetic polymorphism-an uncommon cause of voriconazole treatment failure. Diagnostic microbiology and infectious disease. 2015. Abidi Maheen Z, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. Drug metabolism and disposition: the biological fate of chemicals. 2015. Chaudhry Amarjit S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians. International journal of clinical pharmacy. 2015. Chawla Prerna K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlation Between SNPs in Candidate Genes and VerifyNow-Detected Platelet Responsiveness to Aspirin and Clopidogrel Treatment. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2015. Cui Hanbin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients. International journal of cardiology. 2015. Yang Jie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2015. Niu Xuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation. Journal of cardiology. 2015. Tabata Noriaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics. 2015. Marsh Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. The Journal of antimicrobial chemotherapy. 2015. Trubiano J A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. The pharmacogenomics journal. 2015. So D Y F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes. Therapeutic drug monitoring. 2015. Yamamoto Yoshiaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome. Thrombosis and haemostasis. 2015. Hochholzer W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. Thrombosis research. 2015. Hokimoto Seiji, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in pancreatic cancer patients. British journal of clinical pharmacology. 2015. Kattel Krishna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. International clinical psychopharmacology. 2015. Cabaleiro Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. International journal of cardiology. 2015. Samardzic Jure, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis. Pharmacogenomics. 2015. Kupstyte Nora, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology. 2015. Hodgson Karen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients. Antimicrobial agents and chemotherapy. 2015. Mori Masaaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy. European journal of clinical pharmacology. 2015. Chang Ming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2015. Jeong Tae-Dong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. European journal of clinical pharmacology. 2015. Hashi Sachiyo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical applications of CYP genotyping in psychiatry. Journal of neural transmission (Vienna, Austria : 1996). 2015. Spina Edoardo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease. Balkan journal of medical genetics : BJMG. 2014. Sen H M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. British journal of clinical pharmacology. 2014. Mouly S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. Drug design, development and therapy. 2015. Chung Hyewon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene. 2014. Wang Xia-Qin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study. Journal of the American Heart Association. 2015. McDonough Caitrin W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: ibuprofen pathways. Pharmacogenetics and genomics. 2014. Mazaleuskaya Liudmila L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics and cardiology: improving treatment with existing drugs. Pharmacogenomics. 2015. Sorrentino Matthew J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics. 2015. Sosa-Macias Martha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. 2015. Helton Sarah G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach. PloS one. 2015. Lin Guigao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. Therapeutics and clinical risk management. 2015. Saab Yolande B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. Clinical and experimental pharmacology & physiology. 2014. Pedersen Rasmus Steen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. International journal of antimicrobial agents. 2014. Wang Taotao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of antimicrobial agents. Pharmacogenomics. 2014. Aung Ar Kar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: an algorithm to predict on-clopidogrel platelet reactivity. Thrombosis research. 2014. Miura Go, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following PCI and in Asian Populations Treated with Clopidogrel: A Meta-Analysis. Circulation. Cardiovascular genetics. 2014. Sorich Michael J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis. Clinical pharmacokinetics. 2014. Chang Ming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gene Variants in CYP2C19 are Associated with Altered In Vivo Bupropion Pharmacokinetics but not Bupropion Assisted Smoking Cessation Outcomes. Drug metabolism and disposition: the biological fate of chemicals. 2014. Zhu Andy Z X, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. European journal of clinical pharmacology. 2014. Sugimoto Mitsushige, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. European journal of clinical pharmacology. 2014. Snyder Ben D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. European journal of clinical pharmacology. 2014. Hou Xiaowen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thrombosis and haemostasis. 2014. Gurbel P A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. European journal of clinical pharmacology. 2014. Waade Ragnhild Birkeland, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. Journal of psychopharmacology (Oxford, England). 2014. Kumar Yingying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis. Pharmacogenetics and genomics. 2014. Zhang Ling Ling, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014. Gentile Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. Pharmacogenomics. 2014. Lima John J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Human psychopharmacology. 2014. Cabaleiro Teresa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. Pharmacogenomics. 2014. Calcagno Andrea, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation. The pharmacogenomics journal. 2014. Takahashi M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2014. Tatarunas Vacis, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer chemotherapy and pharmacology. 2014. Mwinyi Jessica, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping. Pharmacogenetics and genomics. 2014. Langaee Taimour Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Analysis of compound heterozygous CYP2C19 genotypes to determine cis and trans configurations. Pharmacogenomics. 2014. Skierka Jennifer M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 2014. Brown Andrew Mk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014. Mizzi Clint, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics. 2014. Zai Gwyneth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Resolution of a clinical AmpliChip CYP450 Test™ no call: discovery and characterization of novel CYP2D6*1 haplotypes. Pharmacogenomics. 2014. Gaedigk Andrea, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics. 2014. Hicks J Kevin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. The Journal of infectious diseases. 2014. Zonios Dimitrios, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. Therapeutic drug monitoring. 2014. Saruwatari Junji, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease. Thrombosis and haemostasis. 2014. Erlinge David, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thrombosis research. 2014. Stimpfle Fabian, et al. PubMed
No Dosing Guideline available No Drug Label available